Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world study on discontinuation strategies after MRD negativity in multiple myeloma patients

View Full Paper
Ask AI
Bookmark
Share

Authors

JLJuan Li

Discussion

Loading...

Member takes

Overview

Observational study finds maintenance therapy cessation feasible after MRD negativity in multiple myeloma, implying quality of life improvements.

Key Points

  • Examine the safety of maintenance therapy discontinuation after MRD negativity in multiple myeloma patients.
  • Retrospective observational study of 357 newly diagnosed multiple myeloma patients
  • Patients received induction therapy followed by ASCT and maintenance treatment
  • MRD assessment performed using multi-parameter flow cytometry
  • Analyzed characteristics and MRD dynamics post-discontinuation
  • Median time from achieving MRD negativity to treatment cessation was 44.8 months
  • 48% of patients experienced MRD conversion to positivity
  • MRD negativity maintained for ≥24 months associated with reduced recurrence risk
  • High-risk cytogenetics showed a trend toward higher recurrence risk
  • Duration of sustained MRD negativity was an independent predictor of post-discontinuation MRD resurgence

Cite This Study

Juan Li (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d7c4https://doi.org/10.1182/blood-2025-2209
View Full Paper
Ask AI
Bookmark
Share